Literature DB >> 30315765

ALPK1 Expression Is Associated with Lymph Node Metastasis and Tumor Growth in Oral Squamous Cell Carcinoma Patients.

Po-Ku Chen1, Chun-Hung Hua2, Hui-Ting Hsu3, Tzer-Min Kuo4, Chia-Min Chung5, Chi-Pin Lee4, Ming-Hsui Tsai2, Kun-Tu Yeh6, Ying-Chin Ko7.   

Abstract

Oral squamous cell carcinoma (OSCC) is the most common malignant cancer, with high mortality rates in advanced stages. Recent studies have shown that the expression of ALPK1 mRNA and its inhibitory differentiation function are associated with cancer progression. However, the expression and clinicopathologic features of ALPK1 in OSCC remain unexplored. Herein, the authors investigated the expression patterns of ALPK1 in 39 matched OSCC patients and examined the relationship between ALPK1 protein expression and clinicopathologic factors using immunohistochemical scores. Using Western blot analysis, ALPK1 expression was found to be significantly higher in tumor tissues than that in nontumor tissues. Through an immunoreactive scoring system, a significantly higher number of advanced-stage tumor size T4 and lymph node metastasis N2 exhibited higher ALPK1 expression levels than that exhibited by T1/T2/T3 tumors and N0/N1. In addition, ALPK1 protein expression was aberrant in malignant oral cancer cell lines compared with that in pre-malignant oral epithelial cells, whereas minimal expression was observed in normal oral epithelial cells. Knockdown of ALPK1 resulted in a significant reduction in cell growth, migration, and invasion capacity in vitro. Consequently, expression of N-cadherin and vimentin decreased in ALPK1-deficient cells. Thus, these results suggest that ALPK1 serves as a potential biomarker and target for OSCC development in late stages.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30315765     DOI: 10.1016/j.ajpath.2018.09.003

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  4 in total

1.  Differential gene expression of ABCG2, SLC22A12, IL-1β, and ALPK1 in peripheral blood leukocytes of primary gout patients with hyperuricemia and their comorbidities: a case-control study.

Authors:  Paniagua-Díaz Natsuko; Sanchez-Chapul Laura; Clavijo-Cornejo Denise; Ventura-Ríos Lucio; Aguilar-Salinas Carlos; Sanchez-Muñoz Fausto; López-Macay Ambar
Journal:  Eur J Med Res       Date:  2022-05-03       Impact factor: 4.981

2.  ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma.

Authors:  Mamunur Rashid; Michiel van der Horst; Thomas Mentzel; Francesca Butera; Ingrid Ferreira; Alena Pance; Arno Rütten; Bostjan Luzar; Zlatko Marusic; Nicolas de Saint Aubain; Jennifer S Ko; Steven D Billings; Sofia Chen; Marie Abi Daoud; James Hewinson; Sandra Louzada; Paul W Harms; Guia Cerretelli; Carla Daniela Robles-Espinoza; Rajiv M Patel; Louise van der Weyden; Chris Bakal; Jason L Hornick; Mark J Arends; Thomas Brenn; David J Adams
Journal:  Nat Commun       Date:  2019-05-17       Impact factor: 14.919

3.  Screening and identification of biomarkers associated with clinicopathological parameters and prognosis in oral squamous cell carcinoma.

Authors:  Qiqi Wu; Ruoyan Cao; Juan Chen; Xiaoli Xie
Journal:  Exp Ther Med       Date:  2019-09-11       Impact factor: 2.447

4.  Long noncoding RNA HAR1A regulates oral cancer progression through the alpha-kinase 1, bromodomain 7, and myosin IIA axis.

Authors:  Chi-Pin Lee; Albert Min-Shan Ko; Srinivasan Nithiyanantham; Chu-Hu Lai; Ying-Chin Ko
Journal:  J Mol Med (Berl)       Date:  2021-06-07       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.